Biocon Limited
Edelweiss Mutual Fund bought 6,26,000 shares of Biocon Limited for ₹25.04 crore at ₹400.00 apiece in a block deal. This transaction was part of a larger block deal where Mylan Inc. sold its entire 5.64% stake in Biocon.
A leading biotechnology company engaged in the manufacture of innovative pharmaceutical products and research services across multiple therapeutic areas. Biocon specializes in biologics, biosimilars, and small molecule drugs, serving patients in oncology, immunology, and diabetes therapeutics globally. The company operates integrated manufacturing facilities and maintains a strong commitment to developing affordable healthcare solutions for patients in emerging markets worldwide.
AMC subsidiary of Edelweiss Financial Services. Manages over Rs 1.5 lakh crore across equity, debt, hybrid and alternative strategies. CEO Radhika Gupta is the most prominent woman leader in Indian asset management and has built a strong direct investor franchise through social media and investor education. Known for multi-asset and international fund-of-fund offerings.